三重大学教員紹介

職名

准教授

氏名

小埜　良一

生年月

所属	部局	医学系研究科
	学科・専攻	生命医科学専攻
	講座	基礎医学系講座
	教育研究分野	感染症制御医学・分子遺伝学分野

TEL

FAX

E-mail

個人のホームページ

http://www.medic.mie-u.ac.jp/microbiol/

学歴

東京大学大学院医学系研究科
生殖・発達・加齢医学専攻
博士課程修了(2004年)

学位

2004.03 医学博士東京大学

所属学会

日本血液学会日本癌学会日本小児血液学会日本小児科学会日本人類遺伝学会米国血液学会

社会活動

職歴

1995.06 東京大学医学部附属病院小児科
1995.10 関東労災病院小児科
1996.10 東京大学医学部附属病院小児科
1997.04 太田西の内病院小児科
1998.10-2000.3 埼玉県立小児医療センター血液・腫瘍科

2004.04 東京大学医科学研究所造血因子探索寄附研究部門
2005.04 同教員(助手相当)
2005.09 東京大学医科学研究所　細胞療法分野
2007.03 三重大学大学院医学系研究科　感染症制御医学助手/助教
2010.02 同講師
2019.02～同准教授

学術（芸術）賞

日本血液学会奨励賞
三医会緑の風記念三重医学研究振興会賞

専門分野

分子生物学、血液学、腫瘍学、ウイルス学

現在の研究課題

白血病発症の分子機構の解析
偽型ウイルスを用いたウイルス感染機構の解析

担当科目

分子生命体科学、微生物学　

主な業績等

主要論文　責任著者

1. Ono R, Masuya M,Inoue N, Shinmei M, Ishii S, Maegawa Y, Maharjan BD, Katayama N, Nosaka T. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models. PLoS One. 16:e0248425, 2021.

2. Ono R, Masuya M, Ishii S, Katayama N, Nosaka T. Eya2, a target activated by Plzf, is critical for PLZF-RARA-induced leukemogenesis. Mol. Cell. Biol., 37:e00585-16, 2017.

主要論文　筆頭著者(上記責任著者論文除く)

1. Ono R, Masuya M, Nakajima H, Enomoto Y, Miyata E, Nakamura A, Ishii S, Suzuki K, Shibata-Minoshima F, Katayama N, Kitamura T, Nosaka T. Plzf drives MLL-fusion-mediated leukemogenesis specifically in long-term hematopoietic stem cells. Blood, 122:1271-1283, 2013.

2. Ono R, Kumagai H, Nakajima H, Hishiya A, Taki T, Horikawa K, Takatsu K, Satoh T, Hayashi Y, Kitamura T, Nosaka T. Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation. Leukemia, 23:2197-2209, 2009.

3. Ono R, Nakajima H, Ozaki K, Kumagai H, Kawashima T, Taki T, Kitamura T, Hayashi Y & Nosaka T. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J. Clin. Invest., 115: 919-929, 2005.

4. Ono R, Ihara M, Nakajima H, Ozaki K, Kataoka-Fujiwara Y, Taki T, Nagata K, Inagaki M, Yoshida N, Kitamura T, Hayashi Y, Kinoshita M & Nosaka T. Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4. Mol. Cell. Biol., 25: 10965-10978, 2005.

5. Ono R, Taki T, Taketani T, Kawaguchi H, Taniwaki M, Okamura T, Kawa K, Hanada R, Kobayashi M, & Hayashi Y. SEPTIN6, a human homolog to mouse Septin6, is fused to MLL in infant acute myeloid leukemia with complex chromosomal abnormalities involving 11q23 and Xq24. Cancer Res., 62: 333-337, 2002.

6. Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, & Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res., 62: 4075-4080, 2002.

主要論文　2nd author

1. Maharjan BD, Ono R, Nosaka T. Eya2 is critical for the E2A-HLF-mediated immortalization of mouse hematopoietic stem/progenitor cells. Int J Oncol. 54:981-990, 2019.

2. Shimozawa N, Ono R, Shimada M, Shibata H, Takahashi I, Inada H, Takada T, Nosaka T, Yasutomi Y. Cynomolgus monkey induced pluripotent stem cells established by using exogenous genes derived from the same monkey species. Differentiation, 85:131-139, 2013.

3. Suzuki K, Ono R, Ohishi K, Masuya M, Kataoka I, Liu B, Nakamori Y, Ino K, Monma F, Hamada H, Kitamura T, Katayama N, Nosaka T. IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+hematopoietic cells on stromal cells. Int. J. Oncol., 40: 53-62, 2012.

4. Minobe K, Ono R, Matsumine A, Shibata-Minoshima F, Izawa K, Oki T, Kitaura J, Iino T, Takita J, Iwamoto S, Hori H, Komada Y, Uchida A, Hayashi Y, Kitamura T, Nosaka T. Expression of ADAMTS4 in Ewing's sarcoma. Int. J. Oncol., 37:569-581, 2010.

5. Hiwatari M, Ono R, Taki T, Hishiya A, Ishii E, Kitamura T, Hayashi Y, and Nosaka T. Novel gain-of-function mutation in the extracellular domain of the PDGFRA gene in infant acute lymphoblastic leukemia with t(4;11)(q21;q23). Leukemia, 22: 2279-2280, 2008.

主要論文　共著

1. Sawaki A, Miyazaki K, Yamaguchi M, Takeuchi T, Kobayashi K, Imai H, Tawara I, Ono R, Nosaka T, Katayama N. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. Int J Hematol. 111: 686-691, 2020.

2. Takeuchi, T, Yamaguchi M, Kobayashi K, Miyazaki K, Tawara I, Imai H, Ono R, Nosaka T, Tanaka K, Katayama N. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Cancer, 123:1166-1173, 2017.

3. Kobayashi K, Yamaguchi M, Miyazaki K, Imai H, Yokoe K, Ono R, Nosaka T, Katayama N. Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features. Cancer Med., 5:1802-1809, 2016.

4. Liu B, Ohishi K, Orito Y, Nakamori Y, Nishikawa H, Ino K, Suzuki K, Matsumoto T, Masuya M, Hamada H, Mineno J, Ono R, Nosaka T, Shiku H, Katayama N. Manipulation of human early T lymphopoiesis by coculture on human bone marrow stromal cells: potential utility for adoptive immunotherapy. Exp. Hematol., 41:367-376, 2013.

5. Jin G, Matsushita H, Asai S, Tsukamoto H, Ono R, Nosaka T, Yahata T, Takahashi S, Miyachi H. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem. Biophys. Res. Commun., 390:1001-1006, 2009.

6. Watanabe-Okochi N, Oki T, Komeno Y, Kato N, Yuji K, Ono R, Harada Y, Harada H, Hayashi Y, Nakajima H, Nosaka T, Kitaura J, Kitamura T. Possible involvement of RasGRP4 in leukemogenesis. Int. J. Hematol., 89: 470-481, 2009.

7. Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, Komeno Y, Nakajima H, Nosaka T, Inaba T, and Kitamura T. AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood, 111: 4297-4308, 2008.

8. Matsushita H, Nakajima H, Nakamura Y, Tsukamoto H, Tanaka Y, Jin G, Yabe M, Asai S, Ono R, Nosaka T, Sugita K, Morimoto A, Hayashi Y, Hotta T, Ando K, and Miyachi H. C/EBPa and C/EBPe induce the monocytic differentiation of myelomonocytic cells with the MLL-chimeric fusion gene. Oncogene, 27: 6749-6760, 2008.

9. Taki T, Akiyama M, Saito S, Ono R, Taniwaki M, Kato Y, Yuza Y, Eto Y & Hayashi Y. The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22. Oncogene, 24: 5191-5197, 2005.

10. Taketani T, Taki T, Takita J, Ono R, Horikoshi Y, Kaneko Y, Sako M, Hanada R, Hongo T, & Hayashi Y. Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome. Leukemia, 16: 1866-1867, 2002.

11. Taketani T, Taki T, Ono R, Kobayashi Y, Ida K, & Hayashi Y. The chromosome translocation t(7;11)(p15;p15) in acute myeloid leukemia results in fusion of the NUP98 gene with a HOXA cluster gene, HOXA13, but not HOXA9. Genes Chromosomes Cancer, 34: 437-443, 2002.

12. Yamamoto K, Nagata K, Tsurukubo Y, Inagaki K, Ono R, Taki T, Hayashi Y, & Hamaguchi H. Translocation (8;12)(q13;p13) during disease progression in acute myelomonocytic leukemia with t(11;19)(q23;p13.1). Cancer Genet. Cytogenet., 137: 64-67, 2002.

総説

1. 小埜良一、野阪哲哉. 血液腫瘍モデル動物の現状と展望. 日本臨床 78巻増刊3: 152-158, 2020.

2. Kitamura T, Watanabe-Okochi N, Enomoto Y, Nakahara F, Oki T, Komeno Y, Kato N, Doki N, Uchida T, Kagiyama Y, Togami K, Kawabata KC, Nishimura K, Hayashi Y, Nagase R, Saika M, Fukushima T, Asada S, Fujino T, Izawa Y, Horikawa S, Fukuyama T, Tanaka Y, Ono R, Goyama S, Nosaka T, Kitaura J, & Inoue D. Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD). J. Biochem. 159:17-25, 2016.

3. 野阪哲哉、小埜良一. MLL融合遺伝子による白血病発症機構. 血液・腫瘍科, 61:217-223, 2010.

4. 小埜良一．MLL遺伝子再構成を有する小児白血病発症の分子機構．日小血会誌，21: 111-120, 2007.

5. 小埜良一，野阪哲哉．MLL関連白血病の分子病態．血液・腫瘍科，52: 615-624, 2006.

6. Ono R, Nosaka T, & Hayashi Y. Roles of a trithorax group gene, MLL, in hematopoiesis. Int J Hematol., 81: 288-293, 2005.